Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00917579 · ClinicalTrials.gov registry record · Phase 4
Bioequivalence Study Comparing A New 10 Mg Atorvastatin Tablet To A 10 Mg Atorvastatin Commercial Tablet
A Phase 4 study of Hypercholesterolemia, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Completed
- Registry status
- Phase 4
- Development phase
- 76
- Enrollment target
- 1
- Study location
NCT00917579: Completed Phase 4 study of Hypercholesterolemia, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
NCT00917579 is a Phase 4 study of Hypercholesterolemia that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 76 participants, below the 816-participant average among 62 other Hypercholesterolemia trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00917579, a Phase 4 study of Hypercholesterolemia, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 76 participants
- Enrollment target
- 1
- Study location
Study Summary
• To determine whether new 10 mg atorvastatin tablets are bioequivalent to 10 mg commercial atorvastatin tablets (Lipitor®).
Primary Outcome
AUCinf = Area under the plasma concentration-time curve from time 0 (predose) extrapolated to infinite time; measured in nanograms times hour per milliliter (ng•hr/mL).
Conditions Studied
Interventions
- DRUG Atorvastatin
Study Locations (1)
Florida
- Pfizer Investigational Site - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2008-07 |
| Est. Completion | 2008-09 |
| Phase | Phase 4 |
What the finished NCT00917579 record still lists
NCT00917579 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 76 participants, a relatively small participant target, below the 816-participant average among 62 other Hypercholesterolemia trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Hypercholesterolemia appearing as the primary indexed condition, and to 1 intervention - of which Atorvastatin is the first listed.
NCT00917579 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT00917579 about?
NCT00917579 is a clinical study titled "Bioequivalence Study Comparing A New 10 Mg Atorvastatin Tablet To A 10 Mg Atorvastatin Commercial Tablet". • To determine whether new 10 mg atorvastatin tablets are bioequivalent to 10 mg commercial atorvastatin tablets (Lipitor®).
What is the current status of trial NCT00917579?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 76 participants. The study started on 2008-07. Estimated completion is 2008-09.
What conditions does trial NCT00917579 study?
This clinical trial studies the following conditions: Hypercholesterolemia.
What interventions are being tested in trial NCT00917579?
The interventions under investigation include: Atorvastatin (DRUG).
Who is sponsoring clinical trial NCT00917579?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00917579 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypercholesterolemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00917579's enrollment target sits among peer trials
76 44th of 62 higher than 19 of 62 other Hypercholesterolemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypercholesterolemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo
COMPLETED · Phase 4
-
Study to Compare Welchol and TriCor to TriCor Alone in Patients With High Cholesterol
COMPLETED · Phase 4
-
Comparison of the Effect of Vytorin 10/80 Tablet Split Into 4 and Simvastatin 20 Milligrams on Low-density Lipoprotein (LDL) Cholesterol
COMPLETED · Phase 4
-
A Study Comparing CoQ10 Levels While Taking 3 Different Statins
COMPLETED · Phase 4
-
Cholesterol and Pharmacogenetic Study
COMPLETED · Phase 4
-
Randomized Trial of Imaging Versus Risk Factor-Based Therapy for Plaque Regression
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02615184 · 76 participants · Phase 2
A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old
- NCT02821741 · 76 participants · NA
Effects of External Ear Stimulation on Pain Perception and Mood
- NCT03019757 · 76 participants
Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease
- NCT03353584 · 76 participants · NA
Effect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia